Medacta reported its first quarter 2017 financial results.
Here are five highlights:
1. The company's USA Spine Division almost doubled its revenues over the first quarter of 2016.
2. Additionally, Medacta Spine unveiled three products in 2016, including the MySpine Low Profile Guide.
3. In February 2017, the FDA cleared the MectaLIF Anterior Hybrid Interbody Fusion Device. The MectaLIF System is designed to improve in situ stability; native disc space height restoration and lordosis; and long-term maintenance of the spinal balance.
4. The MectaLIF product line now encompasses four configurations, three footprints, two materials and hyperlordotic 20-degree cage options.
5. The FDA also cleared the hyper lordotic option and a 40 x 30 mm footprint to supplement the MectaLIF product suite.